PDF(Pubmed)
Abstract：
The amount of evidence for guideline-directed new heart failure (HFrEF) disease-modifying drugs in the context of chronic kidney disease (CKD) is relatively modest, especially in end-stage CKD. We report a case of dramatic reverse remodelling and disease regression in a naïve HFrEF young woman on haemodialysis treated with sacubitril/valsartan and SGLT2i. At 10-month follow-up, the patient normalized left ventricle and atrial volumes and improved ejection fraction to the normal range, assessed both by echocardiography and cardiac magnetic resonance. Cardiac biomarkers and exercise performance improved consensually. The haemodialysis protocol and the loop diuretic dose were unchanged within the whole period.
摘要：
在慢性肾脏病（CKD）的背景下，指南指导的新型心力衰竭（HFrEF）疾病改善药物的证据相对较少。尤其是在终末期CKD中。我们报告了一例未经sacubitril/缬沙坦和SGLT2i治疗的初治HFrEF年轻女性血液透析的急剧逆转重塑和疾病消退的病例。在10个月的随访中，患者左心室和心房容积恢复正常，射血分数改善至正常范围，通过超声心动图和心脏磁共振进行评估。心脏生物标志物和运动表现一致改善。血液透析方案和环利尿剂剂量在整个时期内没有变化。
